Asset·Oral peptide/small molecule peptide

Danuglipron

Aliases: PF-06882961 · oral GLP-1 small molecule

Danuglipron is a oral peptide/small molecule peptide targeting GLP-1R, developed by Pfizer for multiple indications. As of Aug 15, 2024, its highest verified stage is Phase 2.

Phase 2· verified Aug 15, 2024

Identity

Generic name: danuglipron
Brand names: —
Development codes: PF-06882961
Sponsor / originator: Pfizer
Targets: GLP-1R
Route / formulation: Oral tablet

Development timeline

Phase 2· Type 2 diabetes· Global
As of Aug 15, 2024 · Confidence: high
Source: A study to evaluate safety, tolerability, PK/PD of AMG 133 in adults with obesityDanuglipron phase 2b data reported; once-daily formulation advancing.

Trials

View all →

Registry ID	Phase	Status	Enrollment	Completion
NCT05564117	Phase 2	Completed	400	Sep 1, 2024

Next catalysts

View all →

trial start · company guidance

Pfizer expects to advance danuglipron once-daily formulation into phase 3 in 2025.

Jan 1, 2025 – Jun 30, 2025

Sources

registryprimary record
A study to evaluate safety, tolerability, PK/PD of AMG 133 in adults with obesity
Amgen Inc. · ClinicalTrials.gov · Apr 4, 2018 · NCT03548935